Paving the Way for a New Class of Off-The-Shelf Cellular Cancer Vaccine – Cancer Research Institute
Cancer Research Institute (CRI) shared a post on LinkedIn:
”Researchers from Icahn School of Medicine at Mount Sinai, including CRI Scientific Advisory Council Associate Director Dr. Nina Bhardwaj, have developed a novel method to generate billions of rare immune cells known as conventional type I dendritic cells (cDC1s), potentially paving the way for a new class of off-the-shelf cellular cancer vaccines.
“This is a major step toward the creation of universal cell-based cancer vaccines,” describes Dr. Bhardwaj. “Conventional type I dendritic cells are essential for mobilizing the immune system to fight cancer, but they’re almost impossible to obtain at scale. We’ve now overcome that barrier.”
Explore.”
More posts featuring Cancer Research Institute on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023